Calimmune, Inc. (Purchased by CSL Behring)

Calimmune was founded in 2006 based on breakthrough gene modification and cell delivery technology developed in the labs of Nobel Laureate David Baltimore, Ph.D. (California Institute of Technology), Irvin Chen, Ph.D. (University of California, Los Angeles) and Inder M. Verma, Ph.D. (Salk Institute for Biological Studies). Calimmune is accelerating the promise of gene therapy to liberate patients from chronic and currently incurable diseases. To achieve our ambitious goal, we have built a suite of technologies to advance the delivery, manufacturing, and overall efficiency of these life-changing medicines. Calimmune's lead development programs are novel ex-vivo gene therapies for hematologic diseases. We are privileged to have some of the world’s most respected gene therapy developers, clinicians, scientific advisors and commercialization experts committed to our mission. We are passionate about what we do, and for those we ultimately seek to serve.